After finishing 2018 as one of the worst-performing sectors, it looks like biotech could be a runaway leader this year. The iShares Nasdaq Biotechnology ETF (Nasdaq: IBB) has surged 13% so far this year, nearly four-fold the return on the S&P 500, after having crashed 11.8% last year. Valuation multiples are down and acquisition activity for 2019 is already 26% of last year’s total. —Recommended Link— How To Make Massive Gains When The Market Tumbles Industry veteran invites 50 investors to join him in the world’s only legal market hack that actually works… discover how to bring home an… Read More
After finishing 2018 as one of the worst-performing sectors, it looks like biotech could be a runaway leader this year. The iShares Nasdaq Biotechnology ETF (Nasdaq: IBB) has surged 13% so far this year, nearly four-fold the return on the S&P 500, after having crashed 11.8% last year. Valuation multiples are down and acquisition activity for 2019 is already 26% of last year’s total. —Recommended Link— How To Make Massive Gains When The Market Tumbles Industry veteran invites 50 investors to join him in the world’s only legal market hack that actually works… discover how to bring home an extra $37,000 in the next 365 days or less. Biotech is one of the few industries that should remain relatively immune from worries over the trade war and could be a bright spot in an otherwise volatile year. #-ad_banner-#In perhaps no other industry is stock-picking more important than in biotech. Investor sentiment could boost the entire group, but it will be the individual companies with breakthrough drugs that will provide outsized returns. Get Ready For The 2019 Biotech Boom The market was largely disappointed in biotech acquisitions last year and investors reflected their dissatisfaction in share prices. Passage of… Read More